Mineralys Therapeutics (MLYS) CMO trades shares under 10b5-1 plan

Rhea-AI Filing Summary

Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales. On February 9, 2026, he exercised stock options covering 2,171 shares of common stock at $16 per share and received the underlying common shares.

On the same date, he sold 2,171 shares of Mineralys Therapeutics common stock in an open-market transaction at an average price of $30.21 per share, leaving him with 50,437 common shares held directly and 26,047 stock options outstanding. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 6, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M(1)		2,171	A	$16	52,608	D
Common Stock	02/09/2026		S(1)		2,171	D	$30.21	50,437	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$16	02/09/2026		M(1)			2,171	(2)	02/09/2033	Common Stock	2,171	$0	26,047	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mineralys Therapeutics (MLYS) report for its CMO?

Mineralys Therapeutics reported that its Chief Medical Officer, Rodman David Malcom, exercised stock options for 2,171 shares at $16 and sold 2,171 common shares at $30.21. These transactions occurred on February 9, 2026 under a pre-established Rule 10b5-1 trading plan.

How many Mineralys Therapeutics (MLYS) shares did the CMO sell and at what price?

Rodman David Malcom sold 2,171 shares of Mineralys Therapeutics common stock at an average price of $30.21 per share. This open-market sale took place on February 9, 2026, immediately after exercising stock options for the same number of shares at $16.

Did the Mineralys Therapeutics (MLYS) CMO exercise stock options in this Form 4 filing?

Yes. The CMO exercised a stock option for 2,171 underlying shares of Mineralys Therapeutics common stock at an exercise price of $16 per share on February 9, 2026. The option has an expiration date of February 9, 2033 and had a vesting schedule disclosed.

What is the remaining Mineralys Therapeutics (MLYS) share ownership of the CMO after these transactions?

After the reported transactions, the CMO directly holds 50,437 shares of Mineralys Therapeutics common stock and 26,047 stock options. These figures reflect his beneficial ownership immediately following the February 9, 2026 option exercise and corresponding open-market share sale.

Were the Mineralys Therapeutics (MLYS) insider trades made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans allow insiders to pre-schedule trades, providing structure around transactions while they may later possess material nonpublic information.

What is the vesting schedule for the Mineralys Therapeutics (MLYS) stock option in this Form 4?

The stock option vested 25% of its underlying shares on the first anniversary of the grant date. The remaining shares then vest in 36 substantially equal monthly installments, creating a gradual vesting schedule over several years as described in the filing’s footnotes.